# Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Source: https://onco.cc/trials/nct05059522/  
OnCo record `nct05059522` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Avelumab, Talazoparib, Pemetrexed in ovarian cancer, run by Pfizer, active and no longer recruiting.

## Summary

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing is a phase 3 interventional study registered as NCT05059522 by Pfizer, with 77 participants enrolled, started 2021-09-29 and due to reach its primary completion in 2026-12-31. Interventions recorded: Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib. Conditions listed: Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05059522
- Phase: 3
- Setting: AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.
- Sponsor: Pfizer
- Enrolled: 77

## Sources

- ClinicalTrials.gov NCT05059522: https://clinicaltrials.gov/study/NCT05059522

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Avelumab](https://onco.cc/drugs/avelumab/), [Axitinib](https://onco.cc/drugs/axitinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Talazoparib](https://onco.cc/drugs/talazoparib/), [Utomilumab](https://onco.cc/drugs/utomilumab/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct05059522.json